Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-AI or 2C-B or Dexamethasone

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Decadron (historical), Dexpak (taper pack), Hemady, Ozurdex (intravitreal) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes:
2C-x series (1) · high-potency)]] (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · Stimulant (1) · [[:Category:Corticosteroids|Corticosteroid]] (1) · [[:Category:Glucocorticoids|Glucocorticoid (long-acting (1) · [[:Category:Immunosuppressants|Immunosuppressant]] (1)
mechanism:
None (1) · 5-HT2A partial agonist (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1)
uses:
None (2) · '"`UNIQ--vote-00000E23-QINU`"', '"`UNIQ--vote-00000E24-QINU`"', '"`UNIQ--vote-00000E25-QINU`"', '"`UNIQ--vote-00000E26-QINU`"', '"`UNIQ--vote-00000E27-QINU`"', '"`UNIQ--vote-00000E28-QINU`"', '"`UNIQ--vote-00000E29-QINU`"', '"`UNIQ--vote-00000E2A-QINU`"' (1)
starting dose:
None (2) · Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg) (1)
preparations:
None (2) · 0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; oral solution; 4, 10, 20, 100 mg/mL IV; intravitreal implant (Ozurdex) (1)
fda max:
None (2) · Indication-specific (1)
routes:
None (1) · IM (1) · insufflated (1) · intra-articular (1) · intrathecal (rare) (1) · intravitreal (1) · IV (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Hours (1)
duration:
None (1) · 4-8 h (1) · Biologic 36-72 hours (long-acting) (1)
halflife:
None (1) · Not well characterized (1) · Plasma ~3-4.5 hours; biologic ~36-72 hours'"`UNIQ--ref-00000E2B-QINU`"' (1)
bioavailability:
None (1) · Not well characterized (1) · ~80% (oral)'"`UNIQ--ref-00000E2C-QINU`"' (1)
pregnancy:
None (1) · Not established (1) · Used in antenatal lung maturation (24-34 weeks gestation; 6 mg IM q12h × 4 doses); broader use weighs benefits against fetal HPA suppression.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"